Clinical Overestimation of HER2 Positivity in Early Estrogen and Progesterone Receptor–Positive Breast Cancer and the Value of Molecular Subtyping Using BluePrint

by Ettienne J. Myburgh, Lizanne Langenhoven, Kathleen A. Grant, Lize van der Merwe, Maritha J. Kotze
Published 2017-08-01

The cost impact of unselective vs selective MammaPrint testing in early-stage breast cancer in Southern Africa

by Ettienne J. Myburgh, Josephus J. de Jager, Elizabeth Murray, Kathleen A. Grant, Maritha J. Kotze, Hermanus de Klerk
Published 2021-10-01

Reclassification of early stage breast cancer into treatment groups by combining the use of immunohistochemistry and microarray analysis

by Kathleen A. Grant, Ettienne J. Myburgh, Elizabeth Murray, Fredrieka M. Pienaar, Martin Kidd, Colleen A. Wright, Maritha J. Kotze
Published 2019-03-01

Globally Rare BRCA2 Variants With Founder Haplotypes in the South African Population: Implications for Point-of-Care Testing Based on a Single-Institution BRCA1/2 Next-Generation S...

by Jaco Oosthuizen, Jaco Oosthuizen, Maritha J. Kotze, Maritha J. Kotze, Nicole Van Der Merwe, Ettienne J. Myburgh, Phillip Bester, Nerina C. van der Merwe, Nerina C. van der Merwe
Published 2021-02-01